成都嘉葆药银

Chengdu Jiabao Yaoyin is a China-based biotechnology company focused on the discovery of novel small molecule drugs using its proprietary DNA-encoded library (DEL) platform. Founded in 2017 and headquartered in the Chengdu Tianfu International Bio-Town, the company targets high-value G protein-coupled receptors (GPCRs) and other challenging proteins. Its internal pipeline primarily addresses metabolic diseases, including type 2 diabetes and obesity, alongside research in oncology and inflammation. By integrating DEL screening with advanced medicinal chemistry, Jiabao Yaoyin aims to streamline the transition from hit identification to clinical candidates. The company has established collaborations with regional investment groups and academic institutions to support its early-stage research programs.